Bretuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30 (18):2190–2196. doi:10.1200/JCO.2011.38.0402 53. ADCETRIS [package insert]. Bothell, WA: Seattle Genetisc; 2015. Available ...
(B) Number of 7-AAD and Annexin V double negative cells, representing the viable population, are substantially decreased in floating L-428 cells after Brentuximab-Vedotin (BV) treatment. This effect is less dramatic in L-428 cells adherent to NS cHL fibroblasts. Mean + SEM of three ...